You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDofetilide
Accession NumberDB00204  (APRD00367)
TypeSmall Molecule
GroupsApproved
DescriptionDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. [Wikipedia]
Structure
Thumb
Synonyms
beta-((P-Methanesulfonamidophenethyl)methylamino)methanesulfono-P-phenetidide
Dofetilida
Dofetilide
Dofetilidum
Tikosyn
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DofetilideCapsule.25 mg/1OralGreenstone LLC2016-05-01Not applicableUs
DofetilideCapsule.5 mg/1OralGreenstone LLC2016-05-01Not applicableUs
DofetilideCapsule.125 mg/1OralGreenstone LLC1999-10-01Not applicableUs
TikosynCapsule.125 mg/1OralPfizer Laboratories Div Pfizer Inc1999-10-01Not applicableUs
TikosynCapsule.25 mg/1OralPfizer Laboratories Div Pfizer Inc1999-10-01Not applicableUs
TikosynCapsule.5 mg/1OralPfizer Laboratories Div Pfizer Inc1999-10-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DofetilideCapsule.5 mg/1OralMayne Pharma Inc.2016-06-07Not applicableUs
DofetilideCapsule.25 mg/1OralMayne Pharma Inc.2016-06-07Not applicableUs
DofetilideCapsule.125 mg/1OralMayne Pharma Inc.2016-06-07Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIR4Z9X1N2ND
CAS number115256-11-6
WeightAverage: 441.565
Monoisotopic: 441.139212369
Chemical FormulaC19H27N3O5S2
InChI KeyIXTMWRCNAAVVAI-UHFFFAOYSA-N
InChI
InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
IUPAC Name
N-[4-(2-{[2-(4-methanesulfonamidophenyl)ethyl](methyl)amino}ethoxy)phenyl]methanesulfonamide
SMILES
CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1
Pharmacology
IndicationFor the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Structured Indications
PharmacodynamicsDofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering several orders of magnitude, Dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, Dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.
Mechanism of actionThe mechanism of action of Dofetilide is a blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, IKr. This inhibition of potassium channels results in a prolongation of action potential duration and the effective refractory period of accessory pathways (both anterograde and retrograde conduction in the accessory pathway).
TargetKindPharmacological actionActionsOrganismUniProt ID
Potassium voltage-gated channel subfamily H member 2Proteinyes
inhibitor
HumanQ12809 details
Potassium channel subfamily K member 2Proteinyes
inhibitor
HumanO95069 details
ATP-sensitive inward rectifier potassium channel 12Proteinyes
inhibitor
HumanQ14500 details
Related Articles
Absorption>90%
Volume of distribution
  • 3 L/kg
Protein binding60% -70%
Metabolism

Hepatic

Route of eliminationNot Available
Half life10 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Dofetilide can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Dofetilide can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
AlprazolamThe serum concentration of Dofetilide can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Dofetilide.Approved
AmilorideThe serum concentration of Dofetilide can be increased when it is combined with Amiloride.Approved
AmiodaroneThe serum concentration of Dofetilide can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Dofetilide.Approved
AmlodipineThe serum concentration of Dofetilide can be increased when it is combined with Amlodipine.Approved
AmorolfineThe metabolism of Dofetilide can be decreased when combined with Amorolfine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Dofetilide.Approved
Amphotericin BThe metabolism of Dofetilide can be decreased when combined with Amphotericin B.Approved, Investigational
AN2690The metabolism of Dofetilide can be decreased when combined with AN2690.Investigational
AnagrelideDofetilide may increase the QTc-prolonging activities of Anagrelide.Approved
AnidulafunginThe metabolism of Dofetilide can be decreased when combined with Anidulafungin.Approved, Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
AprepitantThe serum concentration of Dofetilide can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
Arsenic trioxideDofetilide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Dofetilide can be decreased when combined with Artemether.Approved
AsenapineDofetilide may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Dofetilide can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Dofetilide can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Dofetilide can be increased when it is combined with Atorvastatin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Dofetilide.Approved
Bafilomycin A1The metabolism of Dofetilide can be decreased when combined with Bafilomycin A1.Experimental
BedaquilineBedaquiline may increase the QTc-prolonging activities of Dofetilide.Approved
BendroflumethiazideBendroflumethiazide may increase the QTc-prolonging activities of Dofetilide.Approved
Benzoic AcidThe metabolism of Dofetilide can be decreased when combined with Benzoic Acid.Approved
BexaroteneThe serum concentration of Dofetilide can be decreased when it is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Dofetilide can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe metabolism of Dofetilide can be decreased when combined with Bifonazole.Approved
BoceprevirThe serum concentration of Dofetilide can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Dofetilide can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dofetilide can be decreased when it is combined with Bosentan.Approved, Investigational
BumetanideBumetanide may increase the QTc-prolonging activities of Dofetilide.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Dofetilide.Approved
ButenafineThe metabolism of Dofetilide can be decreased when combined with Butenafine.Approved
ButoconazoleThe metabolism of Dofetilide can be decreased when combined with Butoconazole.Approved
CandicidinThe metabolism of Dofetilide can be decreased when combined with Candicidin.Withdrawn
CarbamazepineThe metabolism of Dofetilide can be increased when combined with Carbamazepine.Approved, Investigational
CaspofunginThe metabolism of Dofetilide can be decreased when combined with Caspofungin.Approved
CeritinibThe serum concentration of Dofetilide can be increased when it is combined with Ceritinib.Approved
CeruleninThe metabolism of Dofetilide can be decreased when combined with Cerulenin.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
ChloroxineThe metabolism of Dofetilide can be decreased when combined with Chloroxine.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the QTc-prolonging activities of Dofetilide.Approved
CiclopiroxThe metabolism of Dofetilide can be decreased when combined with Ciclopirox.Approved, Investigational
CilostazolThe serum concentration of Dofetilide can be increased when it is combined with Cilostazol.Approved
CimetidineThe serum concentration of Dofetilide can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Dofetilide can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideDofetilide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramDofetilide may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe serum concentration of Dofetilide can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Dofetilide can be increased when it is combined with Clemastine.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
ClotrimazoleThe metabolism of Dofetilide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Dofetilide.Approved
CobicistatThe serum concentration of Dofetilide can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Dofetilide can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe metabolism of Dofetilide can be decreased when combined with Cordycepin.Investigational
CrizotinibThe serum concentration of Dofetilide can be increased when it is combined with Crizotinib.Approved
CyclosporineThe metabolism of Dofetilide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Dofetilide can be decreased when it is combined with Dabrafenib.Approved
DalfopristinThe serum concentration of Dofetilide can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Dofetilide can be increased when it is combined with Danazol.Approved
DarunavirThe serum concentration of Dofetilide can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dofetilide can be increased when it is combined with Dasatinib.Approved, Investigational
Decanoic AcidThe metabolism of Dofetilide can be decreased when combined with Decanoic Acid.Experimental
DeferasiroxThe serum concentration of Dofetilide can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Dofetilide.Approved
DelavirdineThe serum concentration of Dofetilide can be increased when it is combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Dofetilide.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Dofetilide.Approved
DexamethasoneThe serum concentration of Dofetilide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DihydroergotamineThe serum concentration of Dofetilide can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Dofetilide can be increased when it is combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Dofetilide.Approved
DisopyramideDofetilide may increase the QTc-prolonging activities of Disopyramide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Dofetilide.Approved
DolutegravirThe serum concentration of Dofetilide can be increased when it is combined with Dolutegravir.Approved
DomperidoneDofetilide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Dofetilide.Approved
DoxycyclineThe serum concentration of Dofetilide can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Dofetilide can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
EconazoleThe metabolism of Dofetilide can be decreased when combined with Econazole.Approved
EfavirenzThe serum concentration of Dofetilide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Dofetilide can be decreased when combined with Efinaconazole.Approved
EliglustatDofetilide may increase the QTc-prolonging activities of Eliglustat.Approved
EnzalutamideThe serum concentration of Dofetilide can be decreased when it is combined with Enzalutamide.Approved
EribulinEribulin may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
ErythromycinThe serum concentration of Dofetilide can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramDofetilide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Dofetilide can be decreased when it is combined with Eslicarbazepine acetate.Approved
Etacrynic acidEtacrynic acid may increase the QTc-prolonging activities of Dofetilide.Approved
EtravirineThe serum concentration of Dofetilide can be decreased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Dofetilide.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Dofetilide.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Dofetilide.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Dofetilide.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Dofetilide.Approved, Withdrawn
FluconazoleThe metabolism of Dofetilide can be decreased when combined with Fluconazole.Approved
FlucytosineThe metabolism of Dofetilide can be decreased when combined with Flucytosine.Approved
FluoxetineDofetilide may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolDofetilide may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluvoxamineThe serum concentration of Dofetilide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
FosamprenavirThe serum concentration of Dofetilide can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dofetilide can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Dofetilide.Approved
FosphenytoinThe metabolism of Dofetilide can be increased when combined with Fosphenytoin.Approved
FurosemideFurosemide may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dofetilide can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Dofetilide.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Dofetilide.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
Glycerol PhenylbutyrateThe serum concentration of Dofetilide can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GlyphosateThe metabolism of Dofetilide can be decreased when combined with Glyphosate.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Dofetilide.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
GriseofulvinThe metabolism of Dofetilide can be decreased when combined with Griseofulvin.Approved, Vet Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Dofetilide.Approved
HaloproginThe metabolism of Dofetilide can be decreased when combined with Haloprogin.Approved, Withdrawn
HexetidineThe metabolism of Dofetilide can be decreased when combined with Hexetidine.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Dofetilide.Approved
HydrochlorothiazideHydrochlorothiazide may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the QTc-prolonging activities of Dofetilide.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Dofetilide.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
IbutilideDofetilide may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Dofetilide can be increased when it is combined with Idelalisib.Approved
IloperidoneThe serum concentration of Dofetilide can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Dofetilide can be increased when it is combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Dofetilide.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Dofetilide.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Dofetilide.Approved
IndinavirThe serum concentration of Dofetilide can be increased when it is combined with Indinavir.Approved
IsavuconazoniumThe serum concentration of Dofetilide can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe metabolism of Dofetilide can be decreased when combined with Isoconazole.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
IsoniazidThe serum concentration of Dofetilide can be increased when it is combined with Isoniazid.Approved
IsradipineThe serum concentration of Dofetilide can be increased when it is combined with Isradipine.Approved
ItraconazoleThe metabolism of Dofetilide can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Dofetilide.Approved
IvacaftorThe serum concentration of Dofetilide can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Dofetilide can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe serum concentration of Dofetilide can be increased when it is combined with Lamotrigine.Approved, Investigational
LapatinibThe serum concentration of Dofetilide can be increased when it is combined with Lapatinib.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Dofetilide.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
LidocaineLidocaine may increase the arrhythmogenic activities of Dofetilide.Approved, Vet Approved
LithiumLithium may increase the QTc-prolonging activities of Dofetilide.Approved
LomitapideThe serum concentration of Dofetilide can be increased when it is combined with Lomitapide.Approved
LopinavirThe serum concentration of Dofetilide can be increased when it is combined with Lopinavir.Approved
LovastatinThe serum concentration of Dofetilide can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Dofetilide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Dofetilide can be increased when combined with Lumacaftor.Approved
LumefantrineDofetilide may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe serum concentration of Dofetilide can be increased when it is combined with Lurasidone.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Dofetilide.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Dofetilide.Approved
Megestrol acetateThe serum concentration of Dofetilide can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MetforminThe serum concentration of Dofetilide can be increased when it is combined with Metformin.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Dofetilide.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Dofetilide.Approved
MethyclothiazideMethyclothiazide may increase the QTc-prolonging activities of Dofetilide.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
MetolazoneMetolazone may increase the QTc-prolonging activities of Dofetilide.Approved
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Dofetilide.Approved
MevastatinThe metabolism of Dofetilide can be decreased when combined with Mevastatin.Experimental
MicafunginThe metabolism of Dofetilide can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Dofetilide can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
MiltefosineThe metabolism of Dofetilide can be decreased when combined with Miltefosine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Dofetilide.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Dofetilide.Approved
MitotaneThe serum concentration of Dofetilide can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Dofetilide can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Dofetilide.Approved
MonensinThe metabolism of Dofetilide can be decreased when combined with Monensin.Vet Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
MyxothiazolThe metabolism of Dofetilide can be decreased when combined with Myxothiazol.Experimental
NafcillinThe serum concentration of Dofetilide can be decreased when it is combined with Nafcillin.Approved
NaftifineThe metabolism of Dofetilide can be decreased when combined with Naftifine.Approved
NatamycinThe metabolism of Dofetilide can be decreased when combined with Natamycin.Approved
NefazodoneThe serum concentration of Dofetilide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Dofetilide can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dofetilide can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Dofetilide can be increased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Dofetilide can be increased when it is combined with Nicardipine.Approved
NilotinibThe serum concentration of Dofetilide can be increased when it is combined with Nilotinib.Approved, Investigational
NitroxolineThe metabolism of Dofetilide can be decreased when combined with Nitroxoline.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Dofetilide.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Dofetilide.Approved
NystatinThe metabolism of Dofetilide can be decreased when combined with Nystatin.Approved, Vet Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Dofetilide.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
OlaparibThe serum concentration of Dofetilide can be increased when it is combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Dofetilide.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Dofetilide.Approved
OsimertinibThe serum concentration of Dofetilide can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe metabolism of Dofetilide can be decreased when combined with Oxiconazole.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
pafuramidineThe metabolism of Dofetilide can be decreased when combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Dofetilide can be increased when it is combined with Palbociclib.Approved
PaliperidoneDofetilide may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Dofetilide.Approved
PazopanibThe serum concentration of Dofetilide can be increased when it is combined with Pazopanib.Approved
PentamidineThe metabolism of Dofetilide can be decreased when combined with Pentamidine.Approved
PentobarbitalThe metabolism of Dofetilide can be increased when combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Dofetilide.Approved
PhenobarbitalThe metabolism of Dofetilide can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Dofetilide can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideDofetilide may increase the QTc-prolonging activities of Pimozide.Approved
PiretanidePiretanide may increase the QTc-prolonging activities of Dofetilide.Experimental
PolythiazidePolythiazide may increase the QTc-prolonging activities of Dofetilide.Approved
PosaconazoleThe metabolism of Dofetilide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Dofetilide.Approved
PrimidoneThe metabolism of Dofetilide can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideDofetilide may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe serum concentration of Dofetilide can be increased when it is combined with Prochlorperazine.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Dofetilide.Approved
PropafenonePropafenone may increase the arrhythmogenic activities of Dofetilide.Approved
PropofolThe serum concentration of Dofetilide can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Dofetilide.Approved
QuetiapineDofetilide may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneQuinethazone may increase the QTc-prolonging activities of Dofetilide.Approved
QuinidineThe serum concentration of Dofetilide can be increased when it is combined with Quinidine.Approved
QuinineDofetilide may increase the QTc-prolonging activities of Quinine.Approved
QuinupristinThe serum concentration of Dofetilide can be increased when it is combined with Quinupristin.Approved
RadicicolThe metabolism of Dofetilide can be decreased when combined with Radicicol.Experimental
RanolazineThe serum concentration of Dofetilide can be increased when it is combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Dofetilide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dofetilide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dofetilide can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Dofetilide.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
RitonavirThe serum concentration of Dofetilide can be increased when it is combined with Ritonavir.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
Salicylhydroxamic AcidThe metabolism of Dofetilide can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Dofetilide can be decreased when combined with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Dofetilide.Approved
SaquinavirSaquinavir may increase the arrhythmogenic activities of Dofetilide.Approved, Investigational
SertaconazoleThe metabolism of Dofetilide can be decreased when combined with Sertaconazole.Approved
SertralineSertraline may increase the QTc-prolonging activities of Dofetilide.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
SildenafilThe serum concentration of Dofetilide can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dofetilide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dofetilide can be increased when it is combined with Simeprevir.Approved
SinefunginThe metabolism of Dofetilide can be decreased when combined with Sinefungin.Experimental
SirolimusThe metabolism of Dofetilide can be decreased when combined with Sirolimus.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Dofetilide.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
SotalolDofetilide may increase the QTc-prolonging activities of Sotalol.Approved
St. John's WortThe serum concentration of Dofetilide can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Dofetilide can be increased when it is combined with Stiripentol.Approved
SulconazoleThe metabolism of Dofetilide can be decreased when combined with Sulconazole.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Dofetilide.Approved
SulfisoxazoleThe serum concentration of Dofetilide can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Dofetilide.Approved
TavaboroleThe metabolism of Dofetilide can be decreased when combined with Tavaborole.Approved
TelaprevirThe serum concentration of Dofetilide can be increased when it is combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Dofetilide.Approved
TelithromycinThe serum concentration of Dofetilide can be increased when it is combined with Telithromycin.Approved
TerbinafineThe metabolism of Dofetilide can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Dofetilide.Approved
TerconazoleThe metabolism of Dofetilide can be decreased when combined with Terconazole.Approved
TetrabenazineDofetilide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineDofetilide may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Dofetilide.Approved
ThymolThe metabolism of Dofetilide can be decreased when combined with Thymol.Approved
TicagrelorThe serum concentration of Dofetilide can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Dofetilide can be increased when it is combined with Ticlopidine.Approved
TioconazoleThe metabolism of Dofetilide can be decreased when combined with Tioconazole.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Dofetilide.Approved
TocilizumabThe serum concentration of Dofetilide can be decreased when it is combined with Tocilizumab.Approved
TolnaftateThe metabolism of Dofetilide can be decreased when combined with Tolnaftate.Approved, Vet Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
TorasemideTorasemide may increase the QTc-prolonging activities of Dofetilide.Approved
ToremifeneDofetilide may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
TriamtereneThe serum concentration of Dofetilide can be increased when it is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
TrimethoprimTrimethoprim may decrease the excretion rate of Dofetilide which could result in a higher serum level.Approved, Vet Approved
TrimetrexateThe metabolism of Dofetilide can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineTrimipramine may increase the QTc-prolonging activities of Dofetilide.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Dofetilide.Approved, Vet Approved
VandetanibDofetilide may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Dofetilide.Approved
VemurafenibDofetilide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe serum concentration of Dofetilide can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Dofetilide can be increased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Dofetilide.Approved
VoriconazoleThe metabolism of Dofetilide can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
ZiprasidoneThe serum concentration of Dofetilide can be increased when it is combined with Ziprasidone.Approved
ZuclopenthixolDofetilide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US4959366
General References
  1. Lenz TL, Hilleman DE: Dofetilide, a new class III antiarrhythmic agent. Pharmacotherapy. 2000 Jul;20(7):776-86. [PubMed:10907968 ]
  2. Lenz TL, Hilleman DE: Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter. Drugs Today (Barc). 2000 Nov;36(11):759-71. [PubMed:12845335 ]
  3. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999 Sep 16;341(12):857-65. [PubMed:10486417 ]
External Links
ATC CodesC01BD04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (1.45 MB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9179
Caco-2 permeable-0.6257
P-glycoprotein substrateSubstrate0.6018
P-glycoprotein inhibitor IInhibitor0.6848
P-glycoprotein inhibitor IINon-inhibitor0.7391
Renal organic cation transporterNon-inhibitor0.7308
CYP450 2C9 substrateNon-substrate0.7572
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6699
CYP450 1A2 substrateNon-inhibitor0.6359
CYP450 2C9 inhibitorNon-inhibitor0.5189
CYP450 2D6 inhibitorNon-inhibitor0.7709
CYP450 2C19 inhibitorInhibitor0.544
CYP450 3A4 inhibitorNon-inhibitor0.7715
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6823
Ames testNon AMES toxic0.6193
CarcinogenicityNon-carcinogens0.6038
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5430 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8119
hERG inhibition (predictor II)Inhibitor0.8258
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer pharmaceuticals production corp ltd
Packagers
Dosage forms
FormRouteStrength
CapsuleOral.125 mg/1
CapsuleOral.25 mg/1
CapsuleOral.5 mg/1
Prices
Unit descriptionCostUnit
Tikosyn 250 mcg capsule3.64USD capsule
Tikosyn 125 mcg capsule3.63USD capsule
Tikosyn 500 mcg capsule3.61USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4959366 No1992-09-252012-09-25Us
US6124363 No1998-10-092018-10-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0198 mg/mLALOGPS
logP2.17ALOGPS
logP0.24ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)10.15ChemAxon
pKa (Strongest Basic)8.99ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area104.81 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity113.27 m3·mol-1ChemAxon
Polarizability46.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassSulfanilides
Direct ParentSulfanilides
Alternative Parents
Substituents
  • Sulfanilide
  • Phenethylamine
  • Phenol ether
  • Aralkylamine
  • Alkyl aryl ether
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ: Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol. 2000 Feb;57(2):367-74. [PubMed:10648647 ]
  2. Overholt JL, Ficker E, Yang T, Shams H, Bright GR, Prabhakar NR: HERG-Like potassium current regulates the resting membrane potential in glomus cells of the rabbit carotid body. J Neurophysiol. 2000 Mar;83(3):1150-7. [PubMed:10712445 ]
  3. Finlayson K, Pennington AJ, Kelly JS: [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel? Eur J Pharmacol. 2001 Feb 2;412(3):203-12. [PubMed:11166283 ]
  4. Finlayson K, Turnbull L, January CT, Sharkey J, Kelly JS: [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol. 2001 Oct 26;430(1):147-8. [PubMed:11698075 ]
  5. Ficker E, Jarolimek W, Brown AM: Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels. Mol Pharmacol. 2001 Dec;60(6):1343-8. [PubMed:11723241 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM: Molecular determinants of dofetilide block of HERG K+ channels. Circ Res. 1998 Feb 23;82(3):386-95. [PubMed:9486667 ]
  8. Kang J, Chen XL, Wang H, Ji J, Cheng H, Incardona J, Reynolds W, Viviani F, Tabart M, Rampe D: Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Mol Pharmacol. 2005 Mar;67(3):827-36. Epub 2004 Nov 17. [PubMed:15548764 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Potassium ion leak channel activity
Specific Function:
Ion channel that contributes to passive transmembrane potassium transport (PubMed:23169818). Reversibly converts between a voltage-insensitive potassium leak channel and a voltage-dependent outward rectifying potassium channel in a phosphorylation-dependent manner (PubMed:11319556). In astrocytes, forms mostly heterodimeric potassium channels with KCNK1, with only a minor proportion of function...
Gene Name:
KCNK2
Uniprot ID:
O95069
Molecular Weight:
47092.215 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Roukoz H, Saliba W: Dofetilide: a new class III antiarrhythmic agent. Expert Rev Cardiovasc Ther. 2007 Jan;5(1):9-19. [PubMed:17187453 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Inward rectifier potassium channel activity
Specific Function:
Inward rectifying potassium channel that is activated by phosphatidylinositol 4,5-bisphosphate and that probably participates in controlling the resting membrane potential in electrically excitable cells. Probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues. Inward rectifier potassium channels are characterized by a greater tendency to ...
Gene Name:
KCNJ12
Uniprot ID:
Q14500
Molecular Weight:
49000.6 Da
References
  1. Kiehn J, Wible B, Lacerda AE, Brown AM: Mapping the block of a cloned human inward rectifier potassium channel by dofetilide. Mol Pharmacol. 1996 Aug;50(2):380-7. [PubMed:8700146 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:37